CTOs on the Move

Viela Bio

www.vielabio.com

 
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Dan Jamieson
Associate Director Enterprise Architecture Profile
Diana Atwell
Associate Director, Information Systems Profile

Funding

Viela Bio raised $250M on 02/28/2018

Similar Companies

Moderna

Learn how we’re changing the world of medicine. Discover career opportunities, our product pipeline, and browse media resources. Meet Moderna.

Lathrop

Lathrop is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marlon Ramos at Frange Blue-Hairstylist

Marlon Ramos at Frange Blue-Hairstylist is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precept Life Sciences

Precept Life Sciences is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regado Biosciences

Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes and enhance the patient experience, provide direct therapeutic control to physicians and reduce overall treatment costs.